Oleic acid-embedded nanoliposome as a selective tumoricidal agent

Area of Science:

• Biochemistry
• Nanotechnology
• Oncology

Background:

• HAMLET (Human Alpha-lactalbumin Made LEthal to Tumor cell) exhibits selective tumor cell cytotoxicity.
• Oleic acid is the cytotoxic component of HAMLET, but its water-insolubility poses delivery challenges.
• Liposomes offer a potential vehicle for delivering hydrophobic molecules like oleic acid.

Purpose of the Study:

• To develop and characterize a novel nanolipoplex, LIMLET (LIposome Made LEthal to Tumor cell), for targeted oleic acid delivery.
• To evaluate the in vitro cytotoxicity of LIMLET against human breast (MDA-MB-231) and lung (A549) cancer cell lines.
• To compare LIMLET's efficacy and selectivity against cancer cells versus normal cells (Vero).

Main Methods:

• Fabrication of LIMLET nanolipoplexes encapsulating oleic acid within a lipophilic phospholipid bilayer.
• Characterization of LIMLET particle size (mean diameter 127nm) and oleic acid loading (approx. 90,200 molecules per vesicle).
• Assessment of cytotoxicity using WST-1 assay on MDA-MB-231, A549, and Vero cell lines.

Main Results:

• LIMLET demonstrated significant cytotoxicity against MDA-MB-231 and A549 cancer cells.
• Bare liposomes (without oleic acid) showed no toxicity, confirming oleic acid as the active agent.
• LIMLET exhibited selective, dose-dependent toxicity: LD50 values were 1.3nM for MDA-MB-231, 2.2nM for A549, and 5.7nM for Vero cells.

Conclusions:

• LIMLET effectively delivers oleic acid, exhibiting selective tumoricidal activity.
• The nanolipoplex shows promise as a potential nanodrug for cancer treatment, similar to HAMLET.
• The number of oleic acid molecules within the nanolipoplex appears to correlate with its tumoricidal potency.